Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor.
Open Access
- 1 September 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 137 (5) , 1629-1635
- https://doi.org/10.4049/jimmunol.137.5.1629
Abstract
The biosynthesis and oligosaccharide structure of the human complement regulatory glycoprotein decay-accelerating factor (DAF) were studied in erythrocytes and cell lines. Initial information relative to carbohydrate moieties of DAF was obtained by enzymatic digestions. The 74,000 Mr erythrocyte DAF was lowered 3000 by endoglycosidase F, whereas endoglycosidase H had no effect, indicating one N-linked complex-type unit. Treatment with endo-alpha-N-acetylgalactosaminidase to remove O-linked oligosaccharides resulted in a 48,000 Mr molecule (67% of the Mr shift being due to sialic acid), which decreased to 45,000 Mr after sequential endoglycosidase F treatment. To additionally define the oligosaccharide structure and identify precursors in biosynthetic pathways, DAF was studied in the HL-60 cell line differentiated by vitamin D toward monocytes. Pulse-chase experiments with [35S]methionine revealed a precursor species of 43,000 Mr that underwent an early post-translational modification to a 46,000 Mr intermediate, and subsequently was chased into a mature species of 80,000 Mr that aligned with 125I surface-labeled DAF from these cells. All three forms of DAF were approximately 3000 lower in Mr in the presence of tunicamycin. The two lower Mr DAF species were sensitive to endoglycosidases F and H but not to neuraminidase or endo-alpha-N-acetylgalactosaminidase. In summary, DAF is synthesized as a 43,000 Mr precursor species containing one N-linked high-mannose unit. Before entering the central region of the Golgi, it is converted to a 46,000 Mr species by an as yet unknown post-translational modification. The 46,000 Mr form is converted to the 74,000 Mr (erythrocyte) or 80,000 Mr (leukocyte) membrane form of DAF by the addition of multiple, sialylated O-linked oligosaccharide chains (responsible for the large electrophoretic mobility shift) and conversion of the single N-linked high-mannose unit to a complex-type structure. The cell-specific Mr variation between red and white blood cells arises during this post-translational modification from the 46,000 Mr biosynthetic intermediate to the mature DAF species expressed on the cell surface.This publication has 20 references indexed in Scilit:
- Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.Proceedings of the National Academy of Sciences, 1983
- Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.The Journal of Experimental Medicine, 1983
- O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatusCell, 1983
- endo-beta-N-acetylglucosaminidase F: endoglycosidase from Flavobacterium meningosepticum that cleaves both high-mannose and complex glycoproteins.Proceedings of the National Academy of Sciences, 1982
- Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.The Journal of Immunology, 1982
- Improved cell surface radioiodination of macrophagesJournal of Immunological Methods, 1980
- Action of endo-α-N-acetyl-d-galactosaminidase on synthetic glycosides including chromogenic substratesAnalytical Biochemistry, 1978
- The substrate specificities of endo-β-N-acetylglucosaminidases CII and HBiochemical and Biophysical Research Communications, 1977
- Evidence for the participation of saccharide-lipids in the synthesis of the oligosaccharide chain of ovalbumin.Journal of Biological Chemistry, 1977
- Characterization of an endo-α-N-acetyl galactosaminidase from Diplococcus pneumoniaeBiochemical and Biophysical Research Communications, 1976